Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of “Moderate Buy” by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has received an average rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.17.

A number of research analysts have recently commented on IPSC shares. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Century Therapeutics in a research note on Friday, March 15th. Canaccord Genuity Group raised their price target on shares of Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, March 15th.

Insider Activity

In other Century Therapeutics news, insider Adrienne Farid sold 22,831 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $5.14, for a total transaction of $117,351.34. Following the transaction, the insider now directly owns 114,149 shares in the company, valued at approximately $586,725.86. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 25,509 shares of company stock worth $127,635. Company insiders own 7.60% of the company’s stock.

Institutional Trading of Century Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of IPSC. Tower Research Capital LLC TRC lifted its stake in shares of Century Therapeutics by 27.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 4,157 shares of the company’s stock worth $41,000 after purchasing an additional 904 shares during the last quarter. Barclays PLC raised its holdings in Century Therapeutics by 533.3% in the fourth quarter. Barclays PLC now owns 5,408 shares of the company’s stock worth $28,000 after purchasing an additional 4,554 shares in the last quarter. UBS Group AG purchased a new stake in shares of Century Therapeutics during the fourth quarter valued at about $28,000. Citigroup Inc. boosted its holdings in shares of Century Therapeutics by 1,142.8% in the 2nd quarter. Citigroup Inc. now owns 8,339 shares of the company’s stock valued at $26,000 after buying an additional 7,668 shares in the last quarter. Finally, American International Group Inc. grew its position in shares of Century Therapeutics by 37.1% in the 1st quarter. American International Group Inc. now owns 8,604 shares of the company’s stock worth $108,000 after buying an additional 2,328 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Century Therapeutics Price Performance

Shares of IPSC stock opened at $4.05 on Friday. The company has a market cap of $262.52 million, a PE ratio of -1.77 and a beta of 1.33. Century Therapeutics has a 1 year low of $1.28 and a 1 year high of $5.51. The stock’s 50 day simple moving average is $4.32 and its two-hundred day simple moving average is $3.04.

Century Therapeutics (NASDAQ:IPSC) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.07. The company had revenue of $0.27 million during the quarter, compared to analyst estimates of $1.69 million. Century Therapeutics had a negative net margin of 6,115.12% and a negative return on equity of 54.73%. Equities research analysts expect that Century Therapeutics will post -2.02 EPS for the current year.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.